{{Drugbox
| IUPAC_name = (''3R'')-''N''-methoxyquinuclidine-3-carboximidoyl cyanide hydrochloride
| image = Sabcomeline skeletal.svg

<!--Clinical data-->
| tradename = 
| pregnancy_category = 
| legal_status = Never marketed
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!--Identifiers-->
| CAS_number = 159912-58-0
| ATC_prefix = None
| PubChem = 9577995
| IUPHAR_ligand = 306
| ChemSpiderID = 7852359
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = P8P92V596C
| ChEMBL = 134641

<!--Chemical data-->
| C=10 | H=15 | N=3 | O=1 
| molecular_weight = 193.12 g/mol
| smiles = C2CC1CCN2CC1\C(\C#N)=N\OC
}}

'''Sabcomeline''' ('''Memric'''; '''SB-202,026''') is a [[binding_selectivity|selective]] [[muscarinic acetylcholine receptor M1|M<sub>1</sub> receptor]] [[partial agonist]] that was under development for the treatment of [[Alzheimer's disease]].<ref name="pmid9399977">{{cite journal  |vauthors=Loudon JM, Bromidge SM, Brown F, etal | title = SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 283 | issue = 3 | pages = 1059â€“68 |date=December 1997 | pmid = 9399977 | doi = | url = http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9399977}}</ref> It made it to [[phase III]] [[clinical trial]]s before being discontinued due to poor results.

== See also ==
* [[Alvameline]]
* [[Milameline]]
* [[Tazomeline]]
* [[Xanomeline]]

== References ==
{{Reflist}}


{{Nootropics}}
{{Anti-dementia drugs}}
{{Muscarinic acetylcholine receptor modulators}}

[[Category:Muscarinic agonists]]
[[Category:Nitriles]]
[[Category:Oximes]]
[[Category:Quinuclidines]]
[[Category:Experimental drugs]]